• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Diomed Holdings and Duke University Medical Center Create EVLT Center of Excellence

Posted on: Tuesday, 15 November 2005, 12:00 CST

Diomed Holdings, Inc. (AMEX: DIO), a leading developer and marketer of minimally invasive medical technologies and Duke University Medical Center (DUMC), a leading non-profit educational, research and health care institution announced today the formation of a Center of Excellence in the field of venous and arterial disease. The initial focus of the collaboration will be in the field of superficial venous disease with particular emphasis on Diomed's patented EndoVenous Laser Treatment for varicose veins (EVLT(R)).

Under the terms of the three year agreement, Diomed will fund and support a broad array of programs that include basic and advanced training for physicians involved in the diagnosis and comprehensive treatment of venous disease, education for primary care and other referring physicians and activities designed to build patient awareness. Medical programs will include both CME and non-CME courses, while patient education will be delivered via various media and web-based platforms. Diomed and DUMC also plan to collaborate on a number of clinical research projects that will advance the practice of vein and vascular disease management.

"We expect our collaboration with Duke University Medical Center to set a new standard in venous disease education," stated James A. Wylie, President and Chief Executive Officer of Diomed Holdings. "We are particularly pleased to partner with such a prestigious medical institution as Duke. Duke's strong commitment to research, education and achievement of excellence makes it an ideal partner for Diomed."

"Diomed is a leader in the field of endovascular laser treatment of superficial venous disease and varicose veins," commented Dr. Cynthia Shortell, Chief, Division of Vascular Surgery at Duke Medical Center. "As one of the premier medical centers in the United States, we want to be on the leading edge of advancements in this field. This collaboration is a good match with our strategic objectives."

The understanding of superficial venous disease in terms of diagnosis, treatment and impact on a patient's quality of life has advanced significantly over the last decade. Diomed and DUMC have been at the forefront of these changes and now, in collaboration, will look to further advance this rapidly growing medical specialty.

In closing, John Welch, Vice President of North American Marketing for Diomed indicated, "Our partnership with DUMC adds a new dimension to Diomed's physician training program.

Our partnership and alliance with DUMC emphasizes our commitment to physician and patient education and brings our activities in this area to a new level."

About Diomed

Diomed develops and commercializes minimally invasive medical procedures that use its proprietary laser technologies and disposable products. Diomed focuses on EndoVenous Laser Treatment (EVLT(R)) for use in varicose vein treatments, photodynamic therapy (PDT) for use in cancer treatments, and dental and general surgical applications. The EVLT(R) procedure and the Company's related products were cleared by the United States FDA in January of 2002. Along with lasers and single-use procedure kits for EVLT(R), the Company provides its customers with state of the art physician training and practice development support. Additional information is available on the Company's website, www.evlt.com. EVLT(R) is a registered trademark of Diomed, Inc., Andover, MA.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with trends in the products markets, reliance on third party distributors in various countries outside the United States, reoccurring orders under OEM contracts, market acceptance risks, technical development risks and other risk factors. These statements relate to our future plans, objectives, expectations and intentions. These statements may be identified by the use of words such as "may,""will,""should,""potential,""expects,""anticipates,""intends,""plans,""believes" and similar expressions. These statements are based on our current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties. Our actual results could differ materially from those discussed in these statements. Our Annual Report on Form SEC 10-KSB (the "Annual Report") contains a discussion of certain of the risks and uncertainties that affect our business. We refer you to the "Risk Factors" on pages 22 through 37 of the Annual Report for a discussion of certain risks, including those relating to our business as a medical device company without a significant operating record and with operating losses, our risks relating to our commercialization of our current and future products and applications and risks relating to our common stock and its market value. Diomed disclaims any obligation or duty to update or correct any of its forward-looking statements.

Source: Business Wire

More News in this Category